Bleeding time

Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX

Retrieved on: 
Friday, November 11, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, ACR, FDA, Arthritis, Bleeding, Nonsteroidal anti-inflammatory drug, Trémeau, Pain, Tmax, Perception, 2021 Essex County Council election, Degenerative disease, TRM, NSAID, CV, View, Risk, Pain management, Patient, Chronic pain, Gastrointestinal bleeding, American College, Bleeding time, Traffic barrier, Medication, Pharmaceutical industry, Generic drug, Rheumatology, Rofecoxib

Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.

Key Points: 
  • Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.
  • These patients are often left with the inadequate options of living with pain, or resorting to opioids for pain relief.
  • Tremeau is developing TRM-201 (rofecoxib), a COX-2 selective NSAID, as a potential treatment option for people living with pain whose needs are not satisfied by traditional NSAIDs, Dr. Boice added.
  • VIOXX is a registered trademark of Tremeau Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005054/en/

2022 U.S. Coagulation Testing Market Report: Identify and Evaluate Emerging Business Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Research, Managed Care, General Health, Medical Devices, Hospitals, Health Technology, Clinical Trials, Science, Surgery, Biotechnology, Other Science, Health, ACT, Factor VII, Factor XII, Factor, Factor XI, Factor IX, APTT, Protein S, Activated protein C resistance, Thrombin time, Antithrombin, Bleeding time, Protein C, Factor X, Prothrombin time, Consumables, Factor V, Factor VIII, Prekallikrein, Comparison, Factor XIII, Fibrinogen, Marketing, Retail, Vaccine, Fine chemical, Pharmaceutical industry, Plasmin

The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities in the US coagulation testing market during the next five years.
  • The report is available by section, and can be customized to specific information needs and budget.
  • The report explores business and technological trends in the US coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th

Retrieved on: 
Thursday, October 20, 2022
Pharmaceutical, Health, Neurology, Feinberg School of Medicine, Bureau of Oceans and International Environmental and Scientific Affairs, Migraine, Risk, Practical Management of Pain, VP, Albany Medical Center, Traffic barrier, International Association for the Study of Pain, Bleeding time, Nonsteroidal anti-inflammatory drug, McMaster University Medical School, Pain management, Internal medicine, Chronic pain, History, Gastrointestinal bleeding, Trémeau, MD, National, Q&A, International Association, American Academy, Medication, KOL, NSAID, Stony Brook University, Albany Medical College, American Academy of Neurology, Pharmaceutical industry, Pain, Neurology

Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.

Key Points: 
  • Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.
  • In addition, Tremeaus Founder and CEO Bradford C. Sippy will discuss the companys development pipeline, including Phase III-ready TRM-201 (rofecoxib).
  • Previously marketed as VIOXX, rofecoxib has been shown to have a well-established efficacy profile in multiple indications, including migraine.
  • Tremeaus lead clinical stage product, TRM-201 (rofecoxib), is a COX-2 selective NSAID and a potent non-opioid analgesic with a well-established benefit-risk profile.

Tremeau Receives May Proceed Notification From FDA For Phase III Program in Acute Migraine For TRM-201 (Rofecoxib)

Retrieved on: 
Tuesday, June 14, 2022
Health, FDA, General Health, Research, Science, Pharmaceutical, Biotechnology, Diamond, Haemophilia, Plasma, 1836 U.S. Patent Office fire, Migraine, IND, US FDA, Bleeding time, Food and Drug Administration, Joint meetings of the Australian Parliament, History, Gastrointestinal bleeding, Platelet, Intellectual property, Ibuprofen, Trémeau, Food, Veni, vidi, vici, Drug Safety, PLOS, Diamond S Shipping Group Inc., CNT, Coagulopathy, MD, Population, Heart, GI, Albany Medical Center, FitzGerald dynasty, Lancet, Traffic barrier, Systematic review, Osteoarthritis, Standard of care, Medication, Patient, Chronic pain, Tmax, Etoricoxib, Risk management, Diclofenac, The New England Journal of Medicine, US, Arthritis, NSAID, US Foods, Nonsteroidal anti-inflammatory drug, FDA, Risk, Rheumatoid arthritis, Rofecoxib, Headache, Pharmaceutical industry, Generic drug, Dietary supplement, Naproxen, Celecoxib

Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.

Key Points: 
  • Tremeau Pharmaceuticals today announced it has successfully opened an investigational new drug (IND) application and received a May Proceed Notification from FDA to expand the development program for TRM-201 (rofecoxib), an investigational non-opioid treatment, to include a Phase III program for acute migraine.
  • Previously marketed as VIOXX, rofecoxib is a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID) with a well-established efficacy profile in multiple indications, including acute migraine.
  • Tremeau expects that the development program for TRM-201 will include one Phase III acute efficacy and safety study in migraine.
  • Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.

ProPhase Labs Announces Significant Laboratory Expansion

Retrieved on: 
Monday, June 13, 2022
DNA sequencing, NGS, TK, Whole genome sequencing, Company, Hemostasis, Research, Marketing, Food, Genetic, Immunoassay, OTC, Hematology, Platelet, Genetics, CLIA, RNA, Environment, Nebula Genomics, Failure, COVID-19 testing, Nasdaq, Gene, Urine test strip, Physician, GLOBE, FDM, Bleeding time, Private Securities Litigation Reform Act, RT-PCR, DNA, Laboratory, Media relations, PCR, COVID-19, Prothrombin time, Risk, Prophase, Chromosome, Acquisition, NASDAQ, SEC, Severe acute respiratory syndrome coronavirus 2, Institution, Inherited disorders of trafficking, Heart, Thromboplastin, Dietary supplement, Genomics, WGS, University, Antibiotics, Pharmaceutical industry, Blood product, Vaccine

Garden City, NY, June 13, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it has partnered with world-renowned healthcare diagnostics innovators for new clinical chemistry, immunoassay, hematology, hemostasis and urinalysis analyzers as part of its plan to significantly expand its in-house clinical testing capabilities. State-of-the-art clinical testing equipment has been procured and a new lease executed for additional space at the company’s corporate headquarters in Garden City, New York. Plans are also under way to expand the company’s in-house genomics testing offerings.

Key Points: 
  • ProPhase Labs relocated to its current headquarters in January 2021 and built from scratch a 25,000 square foot state-of-the-art CLIA certified laboratory to support the companys growing COVID-19 testing franchise.
  • Ted Karkus, ProPhase Labs Chief Executive Officer, commented, We are very excited to broaden ProPhases testing capabilities at our Garden City headquarters.
  • ProPhase Diagnostics, Inc. (ProPhase Diagnostics), a wholly-owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19).
  • ProPhase Precision Medicine, Inc. (ProPhase Medicine), a wholly-owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA.

Feinstein Institutes for Medical Research and Spark Biomedical, Inc. advance bioelectric medicine designed to stem excessive blood loss

Retrieved on: 
Thursday, June 2, 2022
Â, Litre, NIDA, Tan, Ambulance, DARPA, Trauma, Nursing, Feinstein Institute for Medical Research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Bleeding time, Northwell Health, Medical research, Medicine, History, Opioid, Cancer, Hospital, Sparrow, Spleen, CEO, Genetics, Operating theater, Quality of life, Molecular medicine, Mental health, VNS, Bleeding, Physician, Patient, Vagus nerve stimulation, Metabolic pathway, Science, PTSD, Adult, Research, Feinstein, LinkedIn, Miniature pig, FDA, GLOBE, Twitter, Clinical trial, Hemostasis, Instagram, Autoimmunity, Pharmaceutical industry, MD, Facebook, Shock

Trauma scenes: First responders could apply the device to trauma victims at accident scenes or in ambulances to slow blood loss prior to hospitalization.

Key Points: 
  • Trauma scenes: First responders could apply the device to trauma victims at accident scenes or in ambulances to slow blood loss prior to hospitalization.
  • Military missions: Before missions where there is potential for physical trauma, soldiers could apply the device prophylactically to curb blood loss if they are wounded.
  • We look forward to working with all of the great scientists at the Feinstein Institutes to realize a life-saving vision set forth over a decade ago.
  • Were making breakthroughs in medicine at the Feinstein Institutes for Medical Research.

Global Coagulation Testing Lab and POC Market (2022 to 2026) - Analysis of Current and Emerging Technologies and Their Potential Market Applications - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022
Health, Medical Devices, Cardiology, ACT, Computer, Factor VII, Factor IX, APTT, Thrombin time, Factor XIII, Coagulation, Heparin-induced thrombocytopenia, Fibrinogen, Protein C, The Queen's Award for Enterprise: Innovation (Technology) (2011), Bleeding time, Factor, Activated protein C resistance, Factor X, Prothrombin time, Factor VIII, Prekallikrein, Factor V, Antithrombin, POC, Protein S, Factor XII, Factor XI, Fine chemical, Plasmin

The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation testing market during the next five years.
  • New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation.
  • Coagulation testing will also become more standardized, offering opportunities for quality control products and services.

Tremeau Pharmaceuticals ASH 2021 Presentations Highlight Unmet Need for Non-Opioid Pain Treatments for Patients with Bleeding Disorders

Retrieved on: 
Monday, December 13, 2021
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Risk, Chronic pain, View, Traffic barrier, Nonsteroidal anti-inflammatory drug, FDA, Trémeau, NSAID, Patient, Migraine, Gastrointestinal bleeding, Bleeding time, VWD, Pharmaceutical industry, Blood

Both online-only presentations were published in ASHs November supplemental issue of Blood.

Key Points: 
  • Both online-only presentations were published in ASHs November supplemental issue of Blood.
  • TRM-201 is an investigational non-opioid pain treatment containing rofecoxib.
  • Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.
  • VIOXX is a registered trademark of Tremeau Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005007/en/

Tremeau Expands Pipeline with Novel Non-Opioid Compound for the Treatment of Acute Pain

Retrieved on: 
Monday, October 25, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Safety, US Foods, Medication, Deuterium, Osteoarthritis, Stomach, Pain, Myocardial infarction, History, Hydrogen, Food and Drug Administration, Hospital for Special Surgery, Ulcer, Randomness, Rheumatoid arthritis, Systematic review, Codeine, Etoricoxib, Paracetamol, Dose, Bleeding time, Dog, Food, Ibuprofen, Perforation, Rehabilitation, Stroke, Peptic ulcer disease, Bleeding, Department, USPTO, Risk, Arthritis, Hospital, Weill Cornell Medicine, PLOS, Nonsteroidal anti-inflammatory drug, Heart, Veni, vidi, vici, MD, Cmax, NSAID, DVT, FitzGerald dynasty, Gastrointestinal bleeding, Trémeau, Lancet, Diclofenac, Patient, FDA, Patent, Extrapyramidal system, Chronic pain, CNT, Pharmaceutical industry, Dietary supplement, TRM-362 (Deuterated Etoricoxib), Tremeau Pharmaceuticals, TRM-362 (DEUTERATED ETORICOXIB), TREMEAU PHARMACEUTICALS

Once issued, the patent will provide composition of matter patent protection for Tremeaus novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.

Key Points: 
  • Once issued, the patent will provide composition of matter patent protection for Tremeaus novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.
  • These studies suggest that TRM-362 could provide similar or greater acute pain efficacy when compared to non-enriched etoricoxib, potentially at a lower dose.
  • The surgical community would welcome a more potent non-opioid pain medication that does not carry the bleeding risk of traditional NSAIDs.
  • We will work proactively with FDA to design a product for acute pain that ensures access only for short-term use.